Synthetic biology and therapeutic strategies for the degenerating brain
暂无分享,去创建一个
[1] J. Salamone,et al. The Mysterious Motivational Functions of Mesolimbic Dopamine , 2012, Neuron.
[2] A. Björklund,et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. , 2014, JAMA neurology.
[3] G. Lutz,et al. Oligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of Spinal Muscular Atrophy , 2009, The Journal of Neuroscience.
[4] Amy L. Byers,et al. Depression and risk of developing dementia , 2011, Nature Reviews Neurology.
[5] Martin Fussenegger,et al. An engineered mammalian band-pass network , 2010, Nucleic acids research.
[6] Jens Boch,et al. Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factors , 2010, Proceedings of the National Academy of Sciences.
[7] M. Isalan,et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice , 2012, Proceedings of the National Academy of Sciences.
[8] J. F. Wright,et al. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] S. G. Stolberg. The biotech death of Jesse Gelsinger. , 1999, The New York times magazine.
[10] D. Houitte,et al. Restricted transgene expression in the brain with cell-type specific neuronal promoters. , 2012, Human gene therapy methods.
[11] M. Ehrlich,et al. Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design , 2011, Gene Therapy.
[12] Dana Carroll,et al. Stimulation of Homologous Recombination through Targeted Cleavage by Chimeric Nucleases , 2001, Molecular and Cellular Biology.
[13] P. Starr,et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. , 2012, Human gene therapy.
[14] Eli J. Fine,et al. DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.
[15] B. Davidson,et al. Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. , 2008, Human gene therapy.
[16] Martin Fussenegger,et al. Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome , 2012, Proceedings of the National Academy of Sciences.
[17] Timothy S. Ham,et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast , 2006, Nature.
[18] R. Bakay,et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial , 2011, Lancet Neurology.
[19] Derick R. Peterson,et al. Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.
[20] H. Okano,et al. Common marmoset as a new model animal for neuroscience research and genome editing technology , 2014, Development, growth & differentiation.
[21] G. Braunstein,et al. Global clinical response in Cushing’s syndrome patients treated with mifepristone , 2014, Clinical endocrinology.
[22] J. I. Izpisúa Belmonte,et al. A Cut above the Rest: Targeted Genome Editing Technologies in Human Pluripotent Stem Cells* , 2013, The Journal of Biological Chemistry.
[23] Sheng Huang,et al. TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain , 2010, Nucleic Acids Res..
[24] D. Burn,et al. Parkinson's disease: The quintessential neuropsychiatric disorder , 2011, Movement disorders : official journal of the Movement Disorder Society.
[25] Megan L. McCain,et al. A tissue-engineered jellyfish with biomimetic propulsion , 2012, Nature Biotechnology.
[26] J. Keith Joung,et al. High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.
[27] Chris Bailey-Kellogg,et al. Open Access Methodology Article Optimization Algorithms for Functional Deimmunization of Therapeutic Proteins , 2022 .
[28] N. Zhang,et al. One-step generation of different immunodeficient mice with multiple gene modifications by CRISPR/Cas9 mediated genome engineering. , 2014, The international journal of biochemistry & cell biology.
[29] M. Menéndez-González. The many questions on the use of biomarkers for neurodegenerative diseases in clinical practice , 2014, Front. Aging Neurosci..
[30] Brian L. Gilmore,et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi , 2008, Proceedings of the National Academy of Sciences.
[31] E. Shapiro,et al. Detection of multiple disease indicators by an autonomous biomolecular computer. , 2011, Nano letters.
[32] Le Cong,et al. Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.
[33] Randall J. Platt,et al. Optical Control of Mammalian Endogenous Transcription and Epigenetic States , 2013, Nature.
[34] N. Bresolin,et al. Antisense Oligonucleotide Therapy for the Treatment of C9ORF72 ALS/FTD Diseases , 2014, Molecular Neurobiology.
[35] Joshy Jacob,et al. The Hybrid Cytomegalovirus Enhancer/Chicken β-Actin Promoter along with Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances the Protective Efficacy of DNA Vaccines1 , 2004, The Journal of Immunology.
[36] Hui Zhao,et al. Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors , 2014, Nucleic acids research.
[37] K. Fernandes,et al. Aging and neurogenesis in the adult forebrain: what we have learned and where we should go from here , 2013, The European journal of neuroscience.
[38] R. Barker,et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial , 2014, The Lancet.
[39] Luke A. Gilbert,et al. CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.
[40] Yan Huang,et al. Induction of angiogenesis in a mouse model using engineered transcription factors , 2002, Nature Medicine.
[41] N. Toni,et al. An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ , 2012, The Journal of Neuroscience.
[42] Michael Söderman,et al. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. , 2012, Journal of neurosurgery.
[43] R. Myers,et al. Identification and functional analysis of human transcriptional promoters. , 2003, Genome research.
[44] N. Nukina,et al. Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein , 2010, Nature Biotechnology.
[45] Charles A. Gersbach,et al. Light-Inducible Spatiotemporal Control of Gene Activation by Customizable Zinc Finger Transcription Factors , 2012, Journal of the American Chemical Society.
[46] V. Lee,et al. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases , 2014, Nature Medicine.
[47] S. Basu,et al. A synthetic multicellular system for programmed pattern formation , 2005, Nature.
[48] C. von Kalle,et al. Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.
[49] Nazanin Mirzaei,et al. Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[50] Neville E. Sanjana,et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.
[51] U. A. Ørom,et al. Molecular mechanisms of long ncRNAs in neurological disorders , 2014, Front. Genet..
[52] J. MulcahyPádraig,et al. Gene Therapy: A Promising Approach to Treating Spinal Muscular Atrophy , 2014 .
[53] Yoshiro Shiba,et al. Lesions of Ventrolateral Prefrontal or Anterior Orbitofrontal Cortex in Primates Heighten Negative Emotion , 2012, Biological Psychiatry.
[54] Erin L. Doyle,et al. Targeting DNA Double-Strand Breaks with TAL Effector Nucleases , 2010, Genetics.
[55] D. Emerich,et al. Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer , 2011, Gene Therapy.
[56] W. Seeley,et al. Genetic Correction of Tauopathy Phenotypes in Neurons Derived from Human Induced Pluripotent Stem Cells , 2013, Stem cell reports.
[57] G. Logroscino,et al. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? , 2014, Current opinion in psychiatry.
[58] S. Kügler,et al. Adeno-associated Virus-mediated, Mifepristone-regulated Transgene Expression in the Brain , 2013, Molecular therapy. Nucleic acids.
[59] M. Häusser,et al. Targeting neurons and photons for optogenetics , 2013, Nature Neuroscience.
[60] C. Mussolino,et al. Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa , 2011, EMBO molecular medicine.
[61] S. Sidhu,et al. Synthetic antibody technologies. , 2014, Current opinion in structural biology.
[62] Steven J. M. Jones,et al. A regulatory toolbox of MiniPromoters to drive selective expression in the brain , 2010, Proceedings of the National Academy of Sciences.
[63] Luis Diambra,et al. Genetically Encoded Sender–Receiver System in 3D Mammalian Cell Culture , 2013, ACS synthetic biology.
[64] Christopher A. Voigt,et al. Genetic programs constructed from layered logic gates in single cells , 2012, Nature.
[65] Christine Kinnon,et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.
[66] J. Os,et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010 , 2011, European Neuropsychopharmacology.
[67] Wei-Ting Hwang,et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.
[68] K. Deisseroth,et al. Optogenetic and Potassium Channel Gene Therapy in a Rodent Model of Focal Neocortical Epilepsy , 2012, Science Translational Medicine.
[69] Stolberg Sg. The biotech death of Jesse Gelsinger. , 1999 .
[70] N. Bresolin,et al. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. , 2014, Clinical therapeutics.
[71] David A. Scott,et al. Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.
[72] Jing Liu,et al. Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression , 2012, Cell.
[73] A. Lang,et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients , 2013, Neurology.
[74] S. Niclou,et al. Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system , 2010, BMC Neuroscience.
[75] Sanjay Pandey. Parkinson's disease: recent advances. , 2012, The Journal of the Association of Physicians of India.
[76] Farshid Guilak,et al. Synergistic and tunable human gene activation by combinations of synthetic transcription factors , 2013, Nature Methods.
[77] C. Ross,et al. Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.
[78] John C. Chaput,et al. Synthetic Genetic Polymers Capable of Heredity and Evolution , 2012, Science.
[79] Gorka Orive,et al. Encapsulated cell therapy for neurodegenerative diseases: from promise to product. , 2014, Advanced drug delivery reviews.
[80] Martin Fussenegger,et al. Reward-based hypertension control by a synthetic brain–dopamine interface , 2013, Proceedings of the National Academy of Sciences.
[81] Jeffrey C. Miller,et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.
[82] Lei Wang,et al. Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos , 2014, Cell.
[83] R. Daniel,et al. Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy , 2012, Gene Therapy.
[84] A. Pastore,et al. Kaleidoscopic protein–protein interactions in the life and death of ataxin-1: new strategies against protein aggregation , 2014, Trends in Neurosciences.
[85] K. Bankiewicz,et al. An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons , 2011, Brain Research.
[86] Y. Doyon,et al. Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme , 2012, Genome research.
[87] Kristy M. Hawkins,et al. Synthetic biology: evolution or revolution? A co-founder's perspective. , 2013, Current opinion in chemical biology.
[88] James E. DiCarlo,et al. RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.
[89] Markus Wieland,et al. Programmable single-cell mammalian biocomputers , 2012, Nature.
[90] F. Gage,et al. Modeling brain disease in a dish: really? , 2012, Cell stem cell.
[91] Yan Ao,et al. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice , 2014, Nature Neuroscience.
[92] D. Holtzman,et al. Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.
[93] Morgan L. Maeder,et al. CRISPR RNA-guided activation of endogenous human genes , 2013, Nature Methods.
[94] W. Ge,et al. TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. , 2014, Cell stem cell.
[95] L. Smeeth,et al. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[96] Elo Leung,et al. A TALE nuclease architecture for efficient genome editing , 2011, Nature Biotechnology.
[97] L. Nissim,et al. A tunable dual-promoter integrator for targeting of cancer cells , 2010, Molecular systems biology.
[98] C. Taghibiglou,et al. Novel Central Nervous System Drug Delivery Systems , 2014, Chemical biology & drug design.
[99] E. Basner-Tschakarjan,et al. Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors , 2014, Front. Immunol..
[100] Y. Hua,et al. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. , 2008, American journal of human genetics.
[101] Mark Isalan,et al. p53 Gene Repair with Zinc Finger Nucleases Optimised by Yeast 1-Hybrid and Validated by Solexa Sequencing , 2011, PloS one.
[102] W. Thies,et al. 2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.
[103] Lauren K. Fong,et al. An Engineered Zinc Finger Protein Activator of the Endogenous Glial Cell Line-Derived Neurotrophic Factor Gene Provides Functional Neuroprotection in a Rat Model of Parkinson's Disease , 2010, The Journal of Neuroscience.
[104] E. Androphy,et al. Splicing of a Critical Exon of Human Survival Motor Neuron Is Regulated by a Unique Silencer Element Located in the Last Intron , 2006, Molecular and Cellular Biology.
[105] Javier Macía,et al. Distributed biological computation with multicellular engineered networks , 2011, Nature.
[106] P. Pivirotto,et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[107] Susan Lindquist,et al. Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations , 2011, Cell.
[108] Samuel Bernard,et al. Neurogenesis in the Striatum of the Adult Human Brain , 2014, Cell.
[109] N. Boulis,et al. Intramuscular administration of a VEGF zinc finger transcription factor activator (VEGF-ZFP-TF) improves functional outcomes in SOD1 rats , 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.
[110] Jeffry D. Sander,et al. Efficient In Vivo Genome Editing Using RNA-Guided Nucleases , 2013, Nature Biotechnology.
[111] D. Craufurd,et al. Psychiatric disorders in preclinical Huntington’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[112] Nazanin Mirzaei,et al. Dose-dependent Neuroprotection of VEGF165 in Huntington's Disease Striatum. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[113] Drew Endy,et al. Measuring the activity of BioBrick promoters using an in vivo reference standard , 2009, Journal of biological engineering.
[114] Pradeep J. Nathan,et al. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases , 2013, Nature Reviews Neuroscience.
[115] J. Stelling,et al. A tunable synthetic mammalian oscillator , 2009, Nature.
[116] L. Shihabuddin,et al. Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis , 2012, Neuron.